Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT04196283 Completed - Clinical trials for Advanced Solid Tumors Cancer

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start date: January 22, 2020
Phase: Phase 1
Study type: Interventional

The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

NCT ID: NCT04193293 Terminated - Clinical trials for Head and Neck Squamous Cell Carcinoma

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Start date: June 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

NCT ID: NCT04191460 Recruiting - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer

GuidedbyLight
Start date: July 12, 2022
Phase: Phase 2
Study type: Interventional

This is a two-staged clinical trial to investigate the feasibility of intraoperative Fluorescence Imaging (FLI) to adequately assess tumor margins in patients with oral cancer using cRGD-ZW800-1.

NCT ID: NCT04188665 Recruiting - Clinical trials for Squamous Cell Carcinoma of Head and Neck

Using MASL to Combat Oral Cancer

Start date: January 29, 2021
Phase: Early Phase 1
Study type: Interventional

This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).

NCT ID: NCT04187872 Terminated - Clinical trials for Hepatocellular Carcinoma

LITT and Pembrolizumab in Recurrent Brain Metastasis

TORCH
Start date: January 10, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS).

NCT ID: NCT04187352 Completed - Clinical trials for Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Start date: December 19, 2019
Phase: Phase 3
Study type: Interventional

Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

NCT ID: NCT04183218 Active, not recruiting - Clinical trials for Stage III Lung Cancer AJCC v8

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

Start date: September 23, 2019
Phase:
Study type: Observational

This trial studies cardiac changes after radiation or chemo-radiation for the treatment of lung or esophageal cancer that has not spread to other places in the body (non-metastatic) or has not come back (non-recurrent). Continuous cardiac monitoring with an implanted device may help to identify cardiac changes that would remain unnoticed, and facilitate the treatment of these early cardiac changes as part of standard care.

NCT ID: NCT04183166 Recruiting - Clinical trials for Squamous Cell Carcinoma of Head and Neck

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

Start date: December 12, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).

NCT ID: NCT04180215 Recruiting - Clinical trials for HPV-Related Squamous Cell Carcinoma

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Start date: December 11, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 & HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.

NCT ID: NCT04177797 Active, not recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Start date: March 20, 2020
Phase: Phase 2
Study type: Interventional

This is a single-institution, single arm trial of Toripalimab with neoadjuvant carboplatin and paclitaxel for locally advanced esophageal squamous cell carcinoma (ESCC).The primary study hypothesis is that the patients who received Toripalimab combined with carboplatin and paclitaxel will increase complete pathologic response rate.